IP Verse

Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator - EP3203840

The patent EP3203840 was granted to Vertex Pharmaceuticals Incorporated on Aug 5, 2020. The application was originally filed on Oct 6, 2015 under application number EP15849396A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3203840

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP15849396A
Filing Date
Oct 6, 2015
Status
Opposition Rejected
Mar 21, 2025
Grant Date
Aug 5, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 5, 2021ELKINGTON AND FIFEADMISSIBLE

Patent Citations (65) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2005164973
DESCRIPTIONUS2006035943
DESCRIPTIONUS2006148863
DESCRIPTIONUS2006148864
DESCRIPTIONUS2014073667
DESCRIPTIONUS2014100155
DESCRIPTIONUS2014274933
DESCRIPTIONUS6329422
DESCRIPTIONUS6992096
DESCRIPTIONUS7202262
DESCRIPTIONUS8247436
DESCRIPTIONUS8476269
DESCRIPTIONUS8865902
DESCRIPTIONWO0152902
DESCRIPTIONWO2004028480
DESCRIPTIONWO2004080972
DESCRIPTIONWO2004091502
DESCRIPTIONWO2004110352
DESCRIPTIONWO2004111014
DESCRIPTIONWO2005035514
DESCRIPTIONWO2005049018
DESCRIPTIONWO2005094374
DESCRIPTIONWO2005120497
DESCRIPTIONWO2006044456
DESCRIPTIONWO2006044502
DESCRIPTIONWO2006044503
DESCRIPTIONWO2006044505
DESCRIPTIONWO2006044682
DESCRIPTIONWO2006099256
DESCRIPTIONWO2006101740
DESCRIPTIONWO2006110483
DESCRIPTIONWO2006127588
DESCRIPTIONWO2007044560
DESCRIPTIONWO2010123822
DESCRIPTIONWO2011113894
DESCRIPTIONWO2012078902
DESCRIPTIONWO2012078909
DESCRIPTIONWO2012154880
DESCRIPTIONWO2012154888
DESCRIPTIONWO2012154967
DESCRIPTIONWO2012158885
DESCRIPTIONWO2013038373
DESCRIPTIONWO2013038378
DESCRIPTIONWO2013038381
DESCRIPTIONWO2013038386
DESCRIPTIONWO2013038390
DESCRIPTIONWO2013061091
DESCRIPTIONWO2013112651
DESCRIPTIONWO2013112699
DESCRIPTIONWO2014078842
DESCRIPTIONWO2014081820
DESCRIPTIONWO2014086687
DESCRIPTIONWO2014099673
DESCRIPTIONWO2014152213
DESCRIPTIONWO2014180562
DESCRIPTIONWO2014210159
DESCRIPTIONWO2015003083
DESCRIPTIONWO2015007516
DESCRIPTIONWO2015007517
DESCRIPTIONWO2015007519
INTERNATIONAL-SEARCH-REPORTWO2014071247
SEARCHWO0230895
SEARCHWO2009032116
SEARCHWO2009064848
SEARCHWO2010123822

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
SEARCH- HOPKINS C R ET AL, "Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 21, ISSN 0960-894X, (20061101), pages 5659 - 5663, (20061101), XP027966155 [X] 1,6-15,20,22,23,28 * compounds 2a-e, 4a-4i, 4k, 4l-m, 4p-z *-
SEARCH- JAIN B C ET AL, "STUDIES IN SULPHANILAMIDES. PART XIII. REACTION WITH DICARBOXYLIC ACIDS. SOME NEW N1- AND N4-ACYL AND HETEROCYCLIC DERIVATIVES", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, INDIAN CHEMICAL SOCIETY, IN, (19470101), vol. 24, ISSN 0019-4522, pages 173 - 176, XP002037442 [X] 1,2,6-8,14,17-21 * compound XIV *-
SEARCH- SOLODUCHO ET AL, "Synthesis of Some Pyrido<2,3-c><1,2,6>triazinone derivatives", JOURNAL FÃœR PRAKTISCHE CHEMIE - CHEMIKER-ZEITUNG,, (19890101), vol. 331, no. 3, ISSN 0941-1216, pages 503 - 506, XP009504111 [X] 1,2,6-12,20,22,23 * compound 1 *-
SEARCH- KETTLE J G ET AL, "N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20040101), vol. 14, no. 2, doi:10.1016/J.BMCL.2003.10.049, ISSN 0960-894X, pages 405 - 408, XP002393948 [X] 1,6-8,10-15,18-20,22,23,28 * compound 19 *
SEARCH- ANILKUMAR GOPINADHAN N ET AL, "II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20111020), vol. 22, no. 1, doi:10.1016/J.BMCL.2011.10.041, ISSN 0960-894X, pages 713 - 717, XP029121479 [X] 1,6-15,18-20,22,23,28 * tables 3, 4; compounds 6c, 6e, 6g, 7a-7s *
SEARCH- WINN M ET AL, "2-(ALKYLAMINO)NICOTINC ACID AND ANALOGS. POTENT ANGIOTENSIN II ANTAGONISTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (19930101), vol. 36, no. 18, doi:10.1021/JM00070A012, ISSN 0022-2623, pages 2676 - 2688, XP002281129 [X] 1,2,6-8,14-24 * Page 2677 - Scheme VII -compound 60 X=CONHSO2C6H5 Page 2679 Table V - compound 32hh *
SEARCH- MATTER H ET AL, "Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (20020101), vol. 45, no. 13, doi:10.1021/JM0111346, ISSN 0022-2623, pages 2749 - 2769, XP002256632 [X] 1,6-9,11,13-15,20,22,23,28 * compound 118 *
SEARCH- PASSARELLA D ET AL, "Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, GB, (20010101), no. 2, doi:10.1039/B009154P, ISSN 0300-922X, pages 127 - 129, XP003017354 [X] 1,6-15,20,22,23,28 * compound 10 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents